Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): a phase 2 gineco study

Date

08 Oct 2016

Session

Poster Display

Presenters

Benoît You

Citation

Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374

Authors

B. You1, F. Joly2, I.L. Ray-Coquard3, C. El Kouri4, A. Mercier-Blas5, D. Berton-Rigaud6, E. Kalbacher7, O. Cojocarasu8, M. Fabbro9, J. Cretin10, A. Zannetti11, S. Abadie-Lacourtoisie12, D. Mollon13, A. Hardy-Bessard14, M. Provansal15, G. Freyer1

Author affiliations

  • 1 Oncologie Médicale, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 2 Oncologie, Centre Francois Baclesse, Caen/FR
  • 3 Service 2b Nord, Centre Léon Bérard, Lyon/FR
  • 4 Oncologie Médicale, Centre Catherine de Sienne, Nantes/FR
  • 5 Oncologie Médicale, Centre Hospitalier Privé de Saint-Grégoire, Saint-Grégoire/FR
  • 6 Oncology, ICO Centre René Gauducheau, Saint-Herblain/FR
  • 7 Radiothérapie - Oncologie, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 8 Médecine Interne Et Oncologie Médicale, Pavillon Reilly, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 9 Médecine B2, ICM Val d'Aurelle, Montpellier/FR
  • 10 Oncologie - Radiothérapie, Polycliniques Kenval - Site Valdegour, Nimes/FR
  • 11 Oncologie Médicale, CH Cholet, Cholet/FR
  • 12 Oncologie Médicale, ICO Paul Papin, Angers/FR
  • 13 Service Radiothérapie Et Oncologie Médicale, Centre Hospitalier Intercommunal de Cornouaille, Quimper/FR
  • 14 Oncologie Médicale, Centre CARIO - HPCA, Plerin-sur-Mer/FR
  • 15 Oncologie Médicale, Institute Paoli Calmettes, 13274 - Marseille/FR
More

Resources

Abstract 3870

Background

Cb + pegylated liposomal doxorubicin (PLD) is standard in OCLR. Because of recurrent PLD shortage, we explored the efficacy and tolerance of Cb-NPLD

Methods

From 11/2012 to 07/2014, 86 pts with OCLR received Cb AUC 5 mg.min/ml and NPLD 50 mg/m2, day 1 q4weeks with prophylactic G-CSF support. Primary objective was disease control rate (DCR) at 12 mos. Disease progression was defined according to GCIG criteria including RECIST, CA125 or clinical deterioration.

Results

A total of 69 pts (80%) completed 6 cycles and 7 (9%) continued up to 9 cycles, with G-CSF support (96%). Pts characteristics were: median age 67 years (range 60-75); serous histology (90%); prior platinum (100%), taxane (94%) and bevacizumab (33%); platinum-free interval 6-12 (PFI) (44%) or > 12 mos (56%); 67 (78%) pts had 1 previous line of chemotherapy (CT) and 19 (22%) had 2. DCR at 12 mos was 40%. Median PFS was 11.4 mos (95% CI: 10.2-13.1). OS is not mature (33% events). Complete response rate was 21% and objective response rate was 58% (95% CI: 47-68), 49% (95% CI: 32-65) and 64% (95% CI: 50-78) in the global population, in pts with 6-12 or > 12 mos PFI, respectively. Grade (G) 3/4 neutropenia, thrombocytopenia and anemia were observed in 23, 13 and 11% respectively with febrile neutropenia in 6%. Non hematological toxicities were the followings: G3 fatigue (13%), nausea (8%), vomiting (6%), hand-foot syndrome (1%), pulmonary embolism (1%); G2 alopecia (39%). Junctional tachycardia (JT) in a pt with JT history was the only cardiac event observed. One pt who did not receive prophylactic G-CSF support died from febrile neutropenia.

Conclusions

Cb + NPLD is an alternative carboplatin-based regimen for OC in late relapse. Activity and toxicity profile are in the range of other regimens, but prophylactic G-CSF support is required.

Clinical trial identification

NCT01705158

Legal entity responsible for the study

ARCAGY-GINECO

Funding

Teva

Disclosure

F. Joly: For consulting or advisory role : Roche, Sanofi, Pfizer For Research funding : Astellas, Pfizer For travel, accomodations, expenses : Roche, Janssen, Novartis. I.L. Ray-Coquard: For consulting or advisory role: Pharmamar, Roche, AstraZeneca, MSD For travel, accomodations, expenses: Pharmamar, Roche. A-C. Hardy-Bessard: For Travel, accomodation, expenses: Astrazeneca, Novartis, Roche G. Freyer: For consulting or advisory role: Teva. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings